1. Serum phosphopeptide profiling for colorectal cancer diagnosis using liquid chromatography-mass spectrometry.
- Author
-
Zhai G, Yang L, Luo Q, Wu K, Zhao Y, and Wang F
- Subjects
- Chromatography, Liquid methods, Double-Blind Method, Humans, Mass Spectrometry methods, Silicon Dioxide, Colorectal Neoplasms diagnosis, Phosphopeptides chemistry
- Abstract
Rationale: The identification and evaluation of novel biomarkers are essential to clinical diagnosis and prognosis of colorectal cancer (CRC). Serum phosphopeptides have been recognized as a potential signature pool for cancers; therefore, we aim to profile the expression of serum phosphopeptides and to evaluate their feasibility in CRC diagnosis., Methods: We conducted the characterization and absolute quantification of endogenous phosphopeptides in sera using liquid chromatography-mass spectrometry analysis in combination with enrichment of phosphopeptides by ZrAs-Fe
3 O4 @SiO2 nanoparticles and use of deuterium-labeled standards. Differentially expressed analysis of four phosphopeptides was performed, generating a two-phosphopeptide-based biomarker, LF3-4 , by logistic regression analysis, where LF3-4 is equal to (5.85 - 5.13 × [F3] - 3.57 × [F4]), and [F3] and [F4] are the concentration of phosphopeptides DpSGEGDFLAEGGGVR and ADpSGEGDFLAEGGGVR in sera, respectively., Results: The LF3-4 values showed significant difference in CRC cases compared with controls, and yielded a specificity of 100%, leading to correct classification of 56 (93%) out of 60 CRC patients, including 12 (92.3%) of 13 CRC cases in stage I. Double-blind validation showed that 97.5% of CRC cases were discriminated accurately., Conclusions: The LF3-4 value was firstly verified to be a potential biomarker for CRC diagnosis, and may expand our view in underlying mechanisms for CRC., (© 2022 John Wiley & Sons Ltd.)- Published
- 2022
- Full Text
- View/download PDF